Clinical and Experimental Reproductive Medicine.2014;41(1):39-39. doi:10.5653/cerm.2014.41.1.39
Clinical and Experimental Reproductive Medicine
to Present ISSN: 2093-8896
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
Clinical and Experimental Reproductive Medicine.2014;41(1):37-38. doi:10.5653/cerm.2014.41.1.37
Clinical and Experimental Reproductive Medicine.2014;41(1):33-36. doi:10.5653/cerm.2014.41.1.33
OBJECTIVE: To estimate the failure rate of medical treatment and to identify variables associated with treatment failure in patients with tubal pregnancy and an initial serum level of human chorionic gonadotropin (HCG) over 10,000 IU/L. METHODS: The inclusion criteria were tubal pregnancy diagnosed using ultrasonography, primary treatment of intramuscular methotrexate injection at one of the four institutions between January 2003 and December 2011, a serum HCG level within two days before treatment>10,000 IU/L, and follow-up data to determine treatment success or failure. Exclusion criteria were other primary treatments besides intramuscular methotrexate injection. The clinicopathologic data of 36 patients were collected and analyzed. RESULTS: Medical treatment failed and surgery was performed in 19 (53%) patients. In univariable analysis, age, parity, and size of the gestational sac were associated with treatment failure, but none of the variables were associated with treatment failure in multivariable analysis. The failure rate in the subgroup with age<33 years and size of gestational sac> or =1.1 cm was significantly higher than those of the other subgroups (82% vs. 41% [mean of the other subgroups], respectively). CONCLUSION: Patients with a serum HCG level>10,000 IU/L who received medical treatment had a high failure rate. Among them, patients aged<33 years and with a gestational sac> or =1.1 cm had an extremely high failure rate.
Chorionic Gonadotropin* ; Female ; Follow-Up Studies ; Gestational Sac ; Humans ; Humans* ; Methotrexate* ; Parity ; Pregnancy ; Pregnancy, Tubal* ; Treatment Failure ; Ultrasonography
Chorionic Gonadotropin* ; Female ; Follow-Up Studies ; Gestational Sac ; Humans ; Humans* ; Methotrexate* ; Parity ; Pregnancy ; Pregnancy, Tubal* ; Treatment Failure ; Ultrasonography
Causes of amenorrhea in Korea: Experience of a single large center.
Clinical and Experimental Reproductive Medicine.2014;41(1):29-32. doi:10.5653/cerm.2014.41.1.29
OBJECTIVE: To investigate the causes of amenorrhea in Korean women. METHODS: Medical records from 1,212 women with amenorrhea who visited the Department of Obstetrics and Gynecology, Asan Medical Center, between January 1989 and December 2011 were retrospectively reviewed. Amenorrhea was categorized as either primary or secondary. RESULTS: Primary amenorrhea was identified in 132 of the patients (10.9%) and secondary amenorrhea in 1,080 (89.1%). The most frequent causes of primary amenorrhea were gonadal dysgenesis (28.0%, 37/132); Mayer-Rokitansky-Kuster-Hauser syndrome (20.0%, 27/132); and constitutional delay and androgen insensitivity syndrome (8.3%, 11/132; 8.3%, 11/132, respectively). Secondary amenorrhea was due to polycystic ovary syndrome (48.4%, 523/1,080); premature ovarian insufficiency (14.0%, 151/1,080); and nutrition-related hypogonadotropic hypogonadism (8.3%, 90/1,080). CONCLUSION: In this retrospective study, gonadal dysgenesis was the most common cause of primary amenorrhea and polycystic ovary syndrome was the most common cause of secondary amenorrhea in Korean women.
Amenorrhea* ; Androgen-Insensitivity Syndrome ; Chungcheongnam-do ; Female ; Gonadal Dysgenesis ; Gynecology ; Humans ; Hypogonadism ; Korea* ; Male ; Medical Records ; Obstetrics ; Polycystic Ovary Syndrome ; Retrospective Studies
Amenorrhea* ; Androgen-Insensitivity Syndrome ; Chungcheongnam-do ; Female ; Gonadal Dysgenesis ; Gynecology ; Humans ; Hypogonadism ; Korea* ; Male ; Medical Records ; Obstetrics ; Polycystic Ovary Syndrome ; Retrospective Studies
Clinical and Experimental Reproductive Medicine.2014;41(1):21-28. doi:10.5653/cerm.2014.41.1.21
OBJECTIVE: To investigate the association of individual follicular fluid (FF) leptin and adiponectin levels with the quality of the corresponding oocyte and embryo. METHODS: We prospectively enrolled 67 women who underwent controlled ovarian hyperstimulation with 89 FF samples. FF and the corresponding oocyte was obtained from a single dominant preovulatory follicle at the time of oocyte retrieval. Concentrations of leptin and adiponectin were measured by enzyme-linked immunosorbent assay in an individual follicle. The oocyte quality, fertilization rate, and corresponding embryo development were assessed. RESULTS: The FF level of leptin was significantly associated with body mass index (r=0.334, p<0.01). The FF adiponectin level was significantly higher in the normal fertilization group than the abnormal fertilization group (p=0.009) in the non-obese women. A lower FF leptin level was associated with a trend toward mature oocytes, normal fertilization, and good embryo quality, although these relationships were not statistically significant. The leptin:adiponectin ratio of FF did not differ significantly according to oocyte and embryo quality. The quality of the oocyte and embryo was not associated with the FF leptin level tertile. However, the normal fertilization rate was positively associated with FF adiponectin level tertile. There was a trend towards improved oocytes and normal fertilization rates with the lowest tertile of the FF leptin:adiponectin ratio, but this difference was not statistically significant. CONCLUSION: Our results suggest that a high FF adiponectin concentration could be a predictor of normal fertilization. However, the FF leptin concentration and leptin:adiponectin ratio is not significantly related to oocyte maturity and corresponding embryo development.
Adipokines* ; Adiponectin ; Body Mass Index ; Embryonic Development* ; Embryonic Structures* ; Enzyme-Linked Immunosorbent Assay ; Female ; Fertilization ; Follicular Fluid* ; Humans ; Leptin ; Oocyte Retrieval ; Oocytes* ; Pregnancy ; Prospective Studies ; Spermatozoa*
Adipokines* ; Adiponectin ; Body Mass Index ; Embryonic Development* ; Embryonic Structures* ; Enzyme-Linked Immunosorbent Assay ; Female ; Fertilization ; Follicular Fluid* ; Humans ; Leptin ; Oocyte Retrieval ; Oocytes* ; Pregnancy ; Prospective Studies ; Spermatozoa*
Amelioration of lipid abnormalities by vitamin therapy in women using oral contraceptives.
Clinical and Experimental Reproductive Medicine.2014;41(1):15-20. doi:10.5653/cerm.2014.41.1.15
OBJECTIVE: Combined oral contraceptives (COCs) have some adverse effects on the serum lipid profile. Because hyperlipidemia is one of the risk factors in cardiovascular diseases, lipid abnormalities should be evaluated in women consuming COCs. Vitamins E and C are known to have beneficial effects on serum lipid profiles. Therefore, in this study, we evaluated the effects of vitamins E and C on serum lipids in women using COCs. METHODS: The study compared changes in lipid parameters with and without vitamin therapy in women consuming COCs compared to those of a control group (40 non-contraceptive users or NCU) for 4 weeks. Total cholesterol and triglyceride, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels along with HDL/LDL ratios were measured for all participants. RESULTS: COC users experienced significantly higher increases in the levels of triglycerides and LDL than non-users (p<0.05). However, no significant differences were noted in the total cholesterol and HDL levels. In the treated COC group receiving vitamins E and C, the HDL level and the HDL/LDL ratio increased and the LDL and triglycerides levels decreased significantly compared with those of the other groups. CONCLUSION: The results of our study indicate that supplementation with antioxidant vitamins E and C restores a normal lipid profile in COC users.
Cardiovascular Diseases ; Cholesterol ; Contraceptives, Oral* ; Contraceptives, Oral, Combined ; Female ; Humans ; Hyperlipidemias ; Lipoproteins ; Risk Factors ; Triglycerides ; Vitamins*
Cardiovascular Diseases ; Cholesterol ; Contraceptives, Oral* ; Contraceptives, Oral, Combined ; Female ; Humans ; Hyperlipidemias ; Lipoproteins ; Risk Factors ; Triglycerides ; Vitamins*
Clinical and Experimental Reproductive Medicine.2014;41(1):9-14. doi:10.5653/cerm.2014.41.1.9
OBJECTIVE: The aim of this study was to evaluate the efficiency of the intracytoplasmic morphologically selected sperm injection (IMSI) technique compared with conventional ICSI and previous ICSI attempts in oligo-astheno-teratozoospermia (OAT) patients. METHODS: The sperms were selected under high magnification (6,600x) and used to induce fertilization in previous ICSI patients by IMSI. These results were compared with previous conventional ICSI cycles in patients with OAT infertility. RESULTS: These results demonstrated no significant difference in the fertilization rate between IMSI and previous ICSI cycles (67.7% vs. 65.0%). However, the pregnancy and implantation rates with IMSI were significantly higher than those of the ICSI cycles (33.3% vs. 12.5% and 14.6% vs. 5.4%, respectively; p<0.05). The miscarriage rate among pregnant patients (18.2% vs. 37.5%) showed no statistically significant difference between groups. CONCLUSION: Compared to conventional ICSI, this study found that IMSI increased the IVF-ET success rates in patients with OAT.
Abortion, Spontaneous ; Avena ; Female ; Fertilization ; Humans ; Infertility ; Pregnancy ; Sperm Injections, Intracytoplasmic* ; Spermatozoa*
Abortion, Spontaneous ; Avena ; Female ; Fertilization ; Humans ; Infertility ; Pregnancy ; Sperm Injections, Intracytoplasmic* ; Spermatozoa*
Clinical and Experimental Reproductive Medicine.2014;41(1):1-8. doi:10.5653/cerm.2014.41.1.1
OBJECTIVE: Estrogen related receptor beta (Esrrb) is a member of the orphan nuclear receptors and may regulate the expression of pluripotency-related genes, such as Oct4 and Nanog. Therefore, in the present study, we have developed a method for delivering exogenous ESRRB recombinant protein into embryos by using cell-penetrating peptide (CPP) conjugation and have analyzed their effect on embryonic development. METHODS: Mouse oocytes and embryos were obtained from superovulated mice. The expression of Oct4 mRNA and the cell number of inner cell mass (ICM) in the in vitro-derived and in vivo-derived blastocysts were first analyzed by real time-reverse transcription-polymerase chain reaction and differential staining. Then 8-cell embryos were cultured in KSOM media with or without 2 microg/mL CPP-ESRRB protein for 24 to 48 hours, followed by checking their integration into embryos during in vitro culture by Western blot and immunocytochemistry. RESULTS: Expression of Oct4 and the cell number of ICM were lower in the in vitro-derived blastocysts than in the in vivo-derived ones (p<0.05). In the blastocysts derived from the CPP-ESRRB-treated group, expression of Oct4 was greater than in the non-treated groups (p<0.05). Although no difference in embryonic development was observed between the treated and non-treated groups, the cell number of ICM was greater in the CPP-ESRRB-treated group. CONCLUSION: Treatment of CPP-ESRRB during cultivation could increase embryos' expression of Oct4 and the formation rate of the ICM in the blastocyst. Additionally, an exogenous delivery system of CPP-conjugated protein would be a useful tool for improving embryo culture systems.
Animals ; Blastocyst ; Blotting, Western ; Cell Count ; Embryonic Development ; Embryonic Structures* ; Estrogens ; Female ; Immunohistochemistry ; Mice* ; Oocytes ; Orphan Nuclear Receptors ; Pregnancy ; RNA, Messenger
Animals ; Blastocyst ; Blotting, Western ; Cell Count ; Embryonic Development ; Embryonic Structures* ; Estrogens ; Female ; Immunohistochemistry ; Mice* ; Oocytes ; Orphan Nuclear Receptors ; Pregnancy ; RNA, Messenger
The Author Response: A cohort study and not a case control study.
Clinical and Experimental Reproductive Medicine.2012;39(3):126-126. doi:10.5653/cerm.2012.39.3.126
Letter to the Editor: A cohort study and not a case control study.
Clinical and Experimental Reproductive Medicine.2012;39(3):125-125. doi:10.5653/cerm.2012.39.3.125
Country
Republic of Korea
Publisher
The Korean Society for Reproductive Medicine
ElectronicLinks
http://ecerm.org/Editor-in-chief
Inn Soo Kang
ikang@cha.ac.kr
Abbreviation
Clin Exp Reprod Med
Vernacular Journal Title
대한생식의학회지
ISSN
2093-8896
EISSN
2233-8241
Year Approved
2007
Current Indexing Status
Currently Indexed
Start Year
Description
Clinical and Experimental Reproductive Medicine (CERM) is an international peer-reviewed journal for the gynecologists, reproductive endocrinologists, urologists and basic scientists providing a recent advancement in our understanding of human and animal reproduction. CERM is an official journal of Pacific Society for Reproductive Medicine, the Korean Society for Reproductive Medicine and Korean Society for Assisted Reproduction.
Current Title
Previous Title
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)